SAN JOSE, Calif.--(BUSINESS WIRE)--The biopharmaceutical contract manufacturing market will grow between 5% and 10% a year over the next five years. With biotechnology companies increasing their reliance on biopharmaceutical contract manufacturing organizations (“CMOs”) for production and other services, industry growth prospects remain cautiously optimistic. In this highly competitive environment, CMOs continue to invest in technologies for improving productivity. For example, CMOs are adopting disposable technologies that, along with high-expression cell lines, lessen the need for large-scale stainless steel tank capacity.
